Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note released on Friday,Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on CLDX. UBS Group assumed coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.50.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $20.57 on Friday. The company’s 50 day moving average price is $23.86 and its two-hundred day moving average price is $28.95. The firm has a market capitalization of $1.36 billion, a P/E ratio of -8.00 and a beta of 1.60. Celldex Therapeutics has a fifty-two week low of $19.83 and a fifty-two week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. On average, analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning bought a new position in Celldex Therapeutics during the third quarter worth $504,000. Emerald Mutual Fund Advisers Trust grew its holdings in Celldex Therapeutics by 92.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 243,795 shares of the biopharmaceutical company’s stock worth $8,287,000 after acquiring an additional 116,832 shares during the period. Emerald Advisers LLC raised its position in shares of Celldex Therapeutics by 129.9% in the 3rd quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock worth $15,506,000 after acquiring an additional 257,773 shares in the last quarter. GSA Capital Partners LLP lifted its stake in shares of Celldex Therapeutics by 191.2% in the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock valued at $548,000 after purchasing an additional 10,581 shares during the period. Finally, KBC Group NV boosted its position in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.